While biotech is known for volatility, established giants with deep pipelines and commercial success offer a compelling blend of innovation and stability. We analyze two leaders, Regeneron and Vertex, and their trajectories for the coming year.
While Vertex's expansion into gene therapy and pain management grabs headlines, its enduring dominance and innovation in the cystic fibrosis market remains the core reason long-term investors are holding tight.
In a landmark move, the U.S. Environmental Protection Agency has officially flagged microplastics and a suite of pharmaceuticals as potential drinking water contaminants, initiating a long path toward possible federal regulation.
An RBC Capital Markets review identifies over a dozen biotech firms, including Arrowhead and Xenon, as prime acquisition targets, while naming eight major pharma companies as likely near-term buyers, highlighting the strategic impact of media deal speculation.
With a potential new kidney disease drug nearing regulatory submission and recent launches gaining traction, Vertex Pharmaceuticals is building a compelling case for significant stock appreciation. Analysts weigh whether its diversified growth strategy can propel shares to new highs.
Cosmo Pharmaceuticals' (SWX:COPN) shares have soared 75% in the past year, but recent volatility and conflicting valuation signals are prompting a critical reassessment of its investment case. We examine the numbers behind the rally.
ANI Pharmaceuticals' shares have retreated over 9% in the past month, sparking debate among investors. While a discounted cash flow model suggests significant undervaluation, traditional P/E metrics paint a different picture. We examine the conflicting signals and what they mean for the specialty pharma company's outlook.
Following a successful $200 million financing, Corvus Pharmaceuticals reports significant R&D investment growth driven by its novel ITK inhibitor, soquelitinib. The company outlines a robust 2026 strategy with multiple Phase II/III trials underway in atopic dermatitis, T-cell lymphoma, and new inflammatory indications, backed by a cash runway extending into 2028.
While some generic pharmaceutical companies exceeded revenue expectations in the fourth quarter, investor sentiment remains tepid, with sector stocks broadly declining post-earnings. We analyze the performances of Amneal, ANI Pharmaceuticals, Amphastar, and Viatris.
Despite a strong 31% rally over the past year, new analysis suggests Jazz Pharmaceuticals (NASDAQ: JAZZ) shares may still be significantly undervalued. We examine the key metrics and what they mean for investors.
Amid a stable yet competitive landscape for hepatitis C treatments, Atea Pharmaceuticals reports solid clinical progress and strategic positioning ahead of a potential commercial launch, backed by a milestone-driven partnership with Merck.
As the dust settles on the fourth-quarter earnings season, the generic pharmaceutical industry presents a complex picture. While ANI Pharmaceuticals posted standout revenue growth, broader sector pressures and mixed performances from peers like Viatris and Amphastar highlight the ongoing challenges of price competition and market sentiment.
A review of Q4 earnings reveals a split performance among generic drugmakers. While ANI Pharmaceuticals posted strong growth, Amphastar Pharmaceuticals missed estimates, highlighting the competitive pressures and selective opportunities within the industry.
Fueled by strong performances from its flagship products, ACADIA Pharmaceuticals reports record annual revenues exceeding $1 billion. The biopharma firm outlines ambitious 2026 targets and provides updates on key clinical and regulatory fronts, including its Alzheimer's psychosis candidate.
Jazz Pharmaceuticals (JAZZ) is set to report its latest quarterly earnings after the bell Tuesday. Investors will be watching to see if the company can maintain its recent streak of exceeding expectations, amid a volatile period for the broader pharmaceuticals sector.
With a robust commercial portfolio led by Dupixent and a deep pipeline of late-stage candidates, Regeneron Pharmaceuticals presents a compelling case for sustained growth, trading at a discount to recent valuations.
At the Guggenheim Biotech Conference, Oric Pharmaceuticals detailed its upcoming catalysts, headlined by a planned Phase 3 initiation for its prostate cancer candidate rinzimetostat in the first half of 2025, while also spotlighting promising CNS activity for its lung cancer asset enozertinib.
Private equity firm Ampersand Capital Partners has acquired Belgium-based Purna Pharmaceuticals, a specialist in liquid and semi-solid drug development and manufacturing. The deal aims to forge a trans-Atlantic partnership with Ampersand's existing platform, MedPharm, creating a comprehensive service provider for topical and transdermal pharmaceuticals.
ANI Pharmaceuticals' stock has delivered impressive returns, surging over 159% in five years. Yet, a deep dive into its valuation reveals a complex picture: while a discounted cash flow model suggests significant upside, its lofty P/E ratio raises questions about near-term price sustainability.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
